Cancer Check Labs Welcomes Dr. Raj Attariwala to Scientific & Medical Advisory Board

Renowned Radiologist, Nuclear Medicine Expert, and Founder/Creator of Prenuvo Scan and Report Joins the Mission to Advance Early Cancer Detection and Longevity-Focused Healthcare.

DALLAS, March 6, 2025 /PRNewswire/ -- Cancer Check Labs is honored to announce that Dr. Raj Attariwala, MD, PhD, FRCPC, a world-renowned expert in whole-body radiology and nuclear medicine, has joined the Cancer Check Labs Scientific & Medical Advisory Board. Dr. Attariwala is a co-author of Oncorads – a global standardized MRI technique for cancer screening, and the emeritus founder and creator of the Prenuvo scan and report. His expertise in PET/CT and whole-body MRI redefined imaging of early cancer detection and preventative healthcare.

A dual board-certified Radiologist and Nuclear Medicine physician, Dr. Attariwala trained at some of the world's most prestigious institutions, including Memorial Sloan Kettering, UCLA and USC. He also holds a PhD in Biomedical Engineering from Northwestern University and has published extensively in peer-reviewed medical and scientific journals. His groundbreaking work in molecular imaging, artificial intelligence-driven diagnostics and precision medicine have helped thousands of patients detect cancer and other life-threatening diseases earlier than ever before. His expertise makes him an invaluable addition to Cancer Check Labs as the company continues to pioneer next-- generation cancer screening solutions aimed at early detection and longevity focused healthcare.

"As a diagnostician and engineer, I recognize that in medicine, there is no such thing as a perfect test, and everyone knows that when it comes to cancer, early detection results in better outcomes. Whole body MRI in its current form is challenging to scale, and what excites me about Cancer Check Labs' approach is that it embraces widely accepted pathologic analytical techniques and provides an early window into cancer detection by identifying whole, intact circulating tumor cells at their earliest of stages versus any other blood test on the market. Tests in cancer screening that aid in certainty of diagnosis for early detection has the potential to save countless lives by giving people more time and more options for treatment." said Dr. Attariwala.

Dr. Attariwala's appointment underscores Cancer Check Labs' commitment to innovation in minimally invasive, highly accurate cancer screening. Throughout his career, he has pushed the boundaries of diagnostics, emphasizing the importance of early detection before symptoms arise, when conditions are most treatable. His work has been widely recognized in the medical community for its role in enhancing preventative healthcare and improving patient outcomes.

Beyond his technological innovations, Dr. Attariwala is a sought-after educator, speaker, and thought leader in diagnostic imaging, longevity science, and precision health. His insights into whole-body imaging and early cancer detection have influenced how clinicians and researchers approach proactive medicine. His addition to Cancer Check Labs' Scientific & Medical Advisory Board will provide strategic guidance as the company continues to refine and expand its cutting-edge solutions.

"We are honored to welcome Dr. Attariwala to our advisory board," said Sumit Rai, Founder, Chairman, and CEO of Cancer Check Labs. "His groundbreaking work in radiology and unwavering commitment to early detection aligns perfectly with our mission of providing the most advanced and accurate cancer screening available today. With his expertise, we will continue to push the boundaries of innovation in cancer diagnostics and longevity-focused healthcare."

Cancer Check Labs is redefining cancer detection by utilizing state-of-the-art technology that goes beyond traditional screening methods. Unlike other tests that rely solely on genetic markers or fragments of DNA, Cancer Check physically isolates whole, intact circulating tumor cells (CTCs) from a simple blood sample. Because CTCs have been detected as early as Stage 0, Cancer Check arguably provides the earliest cancer detection test available today, allowing individuals and healthcare providers to act sooner and improve survival outcomes.

The addition of Dr. Attariwala to the advisory board further strengthens the company's mission to expand access to life-saving early detection technologies and set new standards in preventative healthcare.

About Cancer Check Labs
Cancer Check Labs is on a mission to save lives through early detection. Cancer Check is a test that can screen for 200+ cancers by physically extracting whole, intact circulating tumor cells (CTCs) from a blood sample. Because CTCs have been detected in blood samples as early as Stage 0, Cancer Check arguably provides the earliest cancer detection test available today. Cancer Check Labs is headquartered in Medical District in Dallas, TX.

About Cancer Check
The Cancer Check test is not intended to replace other established evidence-based screening, diagnostic, and medical guidelines and practices for the detection of cancer. Similar to other medical tests, the Cancer Check test is not perfect and has limitations to detect all cancers.

Regulatory Disclaimer:

Cancer Check Labs' clinical laboratory has earned a Federal Certificate of Compliance and Federal Certificate of Registration under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which is Federally regulated by the Centers for Medicare and Medicaid Services (CMS). The Cancer Check test has not been cleared or approved by the Food and Drug Administration (FDA). CMS and FDA are both agencies within the US Department of Health and Human Services (HHS). The Cancer Check test offered by Cancer Check Labs is not intended to diagnose, treat, cure, or prevent any disease and should not replace established, evidence-based screening, diagnostic, or medical guidelines for cancer detection. Like all medical tests, Cancer Check is not perfect and has limitations that may not enable it to detect all cancers.

Medical Advice Disclaimer:

This content does not provide medical or healthcare advice. The information, including but not limited to, text, graphics, images and other material contained here are for informational purposes only. No material in this content is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read in this content.

Forward Looking Statements

The SEC encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. The information in this presentation, material, our website, and our mobile applications contain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes", "will", "assume", and words and terms of similar substance in connection with discussions of future operating or financial performance.

The Company's (Cancer Check Labs') forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Important factors that could cause the Company's actual results to differ materially from those in its forward-looking statements include government regulation, economic, strategic, political and social conditions and the following factors: recent and future changes in technology, science, medicine, healthcare, regulatory conditions, governing laws, patient treatment protocols, health insurance reimbursement policies, healthcare payment policies, and the popularity of the Company's content; changes in the Company's plans, initiatives and strategies, and industry acceptance thereof; changes in the plans, initiatives and strategies of the third parties that distribute, license and/or sell the Company's technology; the Company's ability to renew affiliate agreements on favorable terms; competitive pressures, including as a result of structural industry changes, new entrants, advances in competitive technology, business model changes in hospitals and clinics worldwide, economic conditions, pressure from public interest groups, changes in laws and regulations and other societal or political developments; the Company's ability to deal effectively with economic slowdowns or other economic or market difficulties; changes in foreign exchange rates; increased volatility or decreased liquidity in the capital markets, including any limitation on the Company's ability to access the capital markets for debt securities, refinance its outstanding indebtedness or obtain bank financing on acceptable terms; piracy and the Company's ability to exploit and protect its intellectual property rights in and to its content and other products; the failure to achieve the anticipated benefits of the Company's enterprise efficiency initiatives; the effects of any significant acquisitions, dispositions and other similar transactions by the Company; a disruption or failure of the Company's or its vendors' network and information systems or other technology relied on by the Company; the failure to meet earnings expectations; higher or lower than expected valuations; further dilution from additional financings; the adequacy of the Company's risk management framework; changes in U.S. GAAP or other applicable accounting policies; changes in tax, federal communication and other laws and regulations; currency exchange restrictions and currency devaluation risks in some foreign countries; the effect of union or labor disputes; the impact of terrorist acts, hostilities, natural disasters (including extreme weather) and pandemics; and any other act out of the Company's control.

Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise.

Media Contact:
Sumit Rai
214-444-9436
[email protected]

SOURCE Cancer Check Labs